Pseudomonas aeruginosa 感染支气管扩张症患者生活质量与肺功能下降的临床研究
Determinants of quality of life and pulmonary function decline in Pseudomonas aeruginosa-colonised bronchiectasis: a longitudinal study
一项针对 68 名 Pseudomonas aeruginosa 感染的支气管扩张症患者的纵向研究发现,较低的体重指数与早期的身体、健康感知和呼吸症状相关的生活质量下降有关。慢性感染和黏液型 Pseudomonas aeruginosa 的存在是早期多领域生活质量下降的一致预测因素。这些发现有助于指导临床随访。
Abstract
Pseudomonas aeruginosa (PA) colonisation is a key prognostic factor in non-cystic fibrosis bronchiectasis (BE), associated with pulmonary exacerbations (PE), lung function decline, and poorer health-related quality of life (HRQoL). We aimed to identify clinical and microbiological determinants of HRQoL and pulmonary function decline over one year in PA-colonised BE. We followed sixty-eight PA-colonised BE adults assessing HRQoL (QoL-B v3.1) and spirometry quarterly. Linear mixed-effects models and logistic regression examined body mass index (BMI), colonisation status, PA sputum phenotype, frequency of PE/previous year, and pulmonary function phenotype. Lower BMI was associated with early decline across Physical (β 1.52 [0.69], p = 0.029), Health Perceptions (1.67 [0.59], p = 0.005), and Respiratory Symptoms (1.26 [0.56], p = 0.025) HRQoL domains. Chronic colonisation contributed to early Physical (-17.58 [6.99], p = 0.013) and Social Function (-13.73 [5.86], p = 0.020) decline, while mucoid PA predicted early Physical Function worsening (-15.60 [6.53], p = 0.018). Non-obstructive BE was linked to six-month deterioration in Vitality (-17.17 [8.61], p = 0.047), Social Function (-21.02 [8.69], p = 0.017), and Respiratory Symptoms (-13.28 [6.00], p = 0.028). Mucoid PA and ≥1PE/year were the most consistent predictors of multidomain HRQoL deterioration. These determinants were also associated with forced expiratory volume in one second (FEV₁)/forced vital capacity (FVC) decline. These findings identify factors associated with deterioration in PA-colonised BE, which may inform closer clinical follow-up.
Acknowledgements
We would like to thank the patients for being involved in the study and for their adherence during the follow-up. We thank Dr. Rosanel Amaro from the Department of Pulmonology and Dr. Jorge Puig de la Bellacasa of the Microbiology Department at Hospital Clinic for his support of this study.
Funding
This work was supported by the ISCIII-FEDER (Code: PI18/00145) grant awarded to A.T. and L.F.-B.; the Intramural CIBER Project 2018 (ES18PI01 × 1-2021) awarded to A.T. and L.F.-B.; the ISCIII-FOS (FI19/00090) grant awarded to R.L.-A.; and the CB 06/06/0028/CIBER of Respiratory Diseases (CIBERES), an initiative of the ISCIII. Additional support was provided by the ICREA Academy/Institució Catalana de Recerca i Estudis Avançats awarded to A.T., 2.603/IDIBAPS, and SGR 01148 (2021) from Generalitat de Catalunya, also awarded to A.T. and L.F.-B. Grants from the Sociedad Española de Neumología y Cirugía Torácica (SEPAR) were received in 2016 (Code: 208–2016) and 2019 (Code: 628–2019) by L.F.-B. SEPAR-Chiesi awarded L.B.-F. funding in 2021 for preliminary results, and SEPAR provided a “Beca Becario” grant to L.B.-F. in 2023 (Code: 1478–2023). The funders had no role in the design of the study, data collection, data analysis, interpretation, or writing of the manuscript.
Author information
Author notes
Laia Fernández-Barat and Antoni Torres contributed equally to this work.
Authors and Affiliations
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Fundació Clínic per la Recerca Biomèdica (FCRB), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, (CIBERES, 06/06/0028), Hospital Clínic de Barcelona, Barcelona, Spain
Leticia Bueno-Freire, Patricia Oscanoa-Huamán, Rubén López-Aladid, Nil Vázquez, Alexandre López-Gavin, Albert Gabarrús, Adrián Ceccato, Roberto Cabrera, Miquel Ferrer, Néstor Soler, Laia Fernández-Barat & Antoni Torres
School of Medicine, University of Barcelona, Barcelona, Spain
Leticia Bueno-Freire, Patricia Oscanoa-Huamán, Rubén López-Aladid, Nil Vázquez, Alexandre López-Gavin, Albert Gabarrús, Adrián Ceccato, Roberto Cabrera, Miquel Ferrer, Néstor Soler, Laia Fernández-Barat & Antoni Torres
Spanish Institute for Nursing Research, General Nursing Council of Spain, Madrid, Spain
Leticia Bueno-Freire
Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
Victoria Alcaraz-Serrano
Blanquerna School of Health Science, Ramon Llull University, Barcelona, Spain
Victoria Alcaraz-Serrano
Consorci Sanitari Alt Penedès-Garraf (CSAPG), Barcelona, Spain
Patricia Oscanoa-Huamán
Institute of Respiratory Diseases, Policlinico Foggia - Dept of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
Giulia Scioscia
Critical Care Center, Hospital Universitari Parc Taulí, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Sabadell, Spain
Adrián Ceccato
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
Leticia Bueno-Freire, Patricia Oscanoa-Huamán, Rubén López-Aladid, Adrián Ceccato, Roberto Cabrera, Miquel Ferrer, Néstor Soler, Laia Fernández-Barat & Antoni Torres
Institut Clínic Respiratori, Hospital Clínic de Barcelona, Barcelona, Spain
Miquel Ferrer, Néstor Soler & Antoni Torres
Author notes
Laia Fernández-Barat and Antoni Torres have contributed equally as senior authors.
Authors
- Leticia Bueno-Freire
- Victoria Alcaraz-Serrano
- Patricia Oscanoa-Huamán
- Rubén López-Aladid
- Nil Vázquez
- Alexandre López-Gavin
- Giulia Scioscia
- Albert Gabarrús
- Adrián Ceccato
- Roberto Cabrera
- Miquel Ferrer
- Néstor Soler
- Laia Fernández-Barat
- Antoni Torres
Corresponding authors
Correspondence to Laia Fernández-Barat or Antoni Torres.
Ethics declarations
Competing interests
A. Torres has received grants from MedImmune, Cubist, Bayer, Theravance and Polyphor, and personal fees as an advisory board member from Bayer, Roche, The Medicines Co. and Curetis. He has received bureau fees for keynote speaker presentations from GSK, Pfizer, AstraZeneca and Biotest Advisory Board, which are not related to the study described in this paper. L. Bueno-Freire has a consultancy agreement with CARIOTIPO MH5, S.L., acting as Technical Secretariat for the Expert Group on the Management of Bronchiectasis in Spain, promoted by Insmed Pharmaceuticals Inc. This is unrelated to the study described in this paper. The other authors have nothing to declare.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Bueno-Freire, L., Alcaraz-Serrano, V., Oscanoa-Huamán, P. et al. Determinants of quality of life and pulmonary function decline in Pseudomonas aeruginosa-colonised bronchiectasis: a longitudinal study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-79910-3
Received: 18 February 2026
Accepted: 04 November 2026
Published: 20 November 2026
DOI: https://doi.org/10.1038/s41598-026-79910-3
Keywords
来源:Nature 健康护理主题 · nature.com